Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | FER | P16591 | 1/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CDC25B | P30305 | 3/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208723 | 0.70 | PDGFRA (0.50) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL898371 | 0.68 | LRRK2 (0.48) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL6198503 | 0.67 | MAPT (0.48) | MEN1KMT2ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL3354049 | 0.67 | MAOA (0.38) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL209077 | 0.67 | MAOA (0.38) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL38764 | 0.67 | ACVR1 (0.41) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL3544499 | 0.66 | LRRK2 (0.45) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL209272 | 0.64 | PDGFRA (0.44) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL2419975 | 0.64 | GSK3B (0.46) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL2095985 | 0.62 | KMT2A (0.50) | MAOAMAOBGSK3BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-10-10 | — | — | US | claimed |
| EP-3227282-B1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-03 | — | — | EP | claimed |
| US-10172843-B2 | Piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-01-08 | — | — | US | claimed |
| EP-2552216-B1 | DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID | MILLENNIUM PHARM INC (US) | 2018-01-24 | — | — | EP | claimed |
| EP-3227282-A1 | NOVEL PIPERIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-10-11 | — | — | EP | claimed |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-09-21 | — | — | US | claimed |
| WO-2016087352-A1 | NOVEL PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-09 | — | — | WO | claimed |
| US-9023832-B2 | Derivatives of 1-amino-2-cyclopropylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | claimed |
| US-20140179631-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | claimed |
| US-8513218-B2 | Derivatives of 1-amino-2-cyclopropylethylboronic acid | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | claimed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | claimed |
| EP-1470112-A1 | SUBSTITUTED PYRIDAZINONES AS INHIBITORS OF P38 | Pharmacia Corporation (US) | 2004-10-27 | — | — | EP | claimed |
| WO-2004087677-A2 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS P38 KINASE MODULATORS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | claimed |
| US-20040142932-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | claimed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| US-20040058964-A1 | Substituted pyridinones | PHARMACIA LLC | 2004-03-25 | — | — | US | claimed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| WO-2003059891-A1 | SUBSTITUTED PYRIDAZINONES AS INHIBITORS OF P38 | PHARMACIA CORPORATION (US) | 2003-07-24 | — | — | WO | claimed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307737-A1 | NOVEL PIPERIDINE DERIVATIVES | ADORA1, ADRA1D, ADORA2B | MAOA 763/4885MAOB 837/4885PDGFRA 253/4885 |
| US-20040058964-A1 | Substituted pyridinones | MAPK1, MAPK6, MAPK7 | MAOA 1401/4885MAOB 743/4885PDGFRA 567/4885 |
| US-20140179631-A1 | DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID | PSMB6, PSMB5, PSMB1 | MAOA 1451/4885MAOB 813/4885PDGFRA 2684/4885 |
| US-20170266175-A1 | NOVEL PIPERIDINE DERIVATIVES | ADORA1, ADRA1D, ADORA2B | MAOA 763/4885MAOB 837/4885PDGFRA 253/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAOA 2498/4885MAOB 1814/4885PDGFRA 181/4885 |
| US-10172843-B2 | Piperidine derivatives | ADRA1D, ADORA1, ADRA1A | MAOA 561/4885MAOB 510/4885PDGFRA 90/4885 |
| US-20040142932-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAOA 953/4885MAOB 677/4885PDGFRA 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.